Literature DB >> 16254214

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.

Mark B Pepys1, Philip N Hawkins, Melvyn C Kahan, Glenys A Tennent, J Ruth Gallimore, David Graham, Caroline A Sabin, Arturo Zychlinsky, Juana de Diego.   

Abstract

Intravenous administration to human volunteers of a commercial preparation of recombinant human C-reactive protein (CRP) produced in Escherichia coli was recently reported in this journal to induce an acute phase response of serum amyloid A protein (SAA) and of CRP itself, and to activate the coagulation system. The authors concluded that CRP is probably a mediator of atherothrombotic disease. Here we confirm that this recombinant CRP preparation was proinflammatory both for mouse macrophages in vitro and for mice in vivo, but show that pure natural human CRP had no such activity. Furthermore mice transgenic for human CRP, and expressing it throughout their lives, maintained normal concentrations of their most sensitive endogenous acute phase reactants, SAA and serum amyloid P component (SAP). The patterns of in vitro cytokine induction and of in vivo acute phase stimulation by the recombinant CRP preparation were consistent with contamination by bacterial products, and there was 46.6 EU of apparent endotoxin activity per mg of CRP in the bacterial product, compared with 0.9 EU per mg of our isolated natural human CRP preparation. The absence of any proinflammatory activity in natural CRP for macrophages or healthy mice strongly suggests that the in vivo effects of the recombinant preparation observed in humans were attributable to proinflammatory bacterial products and not human CRP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254214      PMCID: PMC1400607          DOI: 10.1161/01.RES.0000193595.03608.08

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  51 in total

1.  Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease.

Authors:  J Danesh; R Collins; R Peto; G D Lowe
Journal:  Eur Heart J       Date:  2000-04       Impact factor: 29.983

2.  Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization.

Authors:  Toshio Tanaka; Takekazu Horio; Yuhsi Matuo
Journal:  Biochem Biophys Res Commun       Date:  2002-07-05       Impact factor: 3.575

3.  Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells.

Authors:  Yasuko Nagoshi; Kenji Kuwasako; Yuan Ning Cao; Kazuo Kitamura; Tanenao Eto
Journal:  Biochem Biophys Res Commun       Date:  2004-02-20       Impact factor: 3.575

Review 4.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

5.  Toll-like receptors are temporally involved in host defense.

Authors:  David S Weiss; Bärbel Raupach; Kiyoshi Takeda; Shizuo Akira; Arturo Zychlinsky
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

6.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; J R Gallimore; M B Pepys
Journal:  BMJ       Date:  2000-07-22

Review 7.  Pathogenesis, diagnosis and treatment of systemic amyloidosis.

Authors:  M B Pepys
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-02-28       Impact factor: 6.237

8.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Authors:  Gideon M Hirschfield; J Ruth Gallimore; Melvyn C Kahan; Winston L Hutchinson; Caroline A Sabin; G Martin Benson; Amar P Dhillon; Glenys A Tennent; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

9.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

10.  C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.

Authors:  M Griselli; J Herbert; W L Hutchinson; K M Taylor; M Sohail; T Krausz; M B Pepys
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

View more
  37 in total

1.  Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting.

Authors:  Tjörvi E Perry; Jochen D Muehlschlegel; Kuang-Yu Liu; Amanda A Fox; Charles D Collard; Simon C Body; Stanton K Shernan
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

2.  C reactive protein and long-term risk for chronic kidney disease: a historical prospective study.

Authors:  Eitan Kugler; Eytan Cohen; Elad Goldberg; Yuval Nardi; Amos Levi; Irit Krause; Moshe Garty; Ilan Krause
Journal:  J Nephrol       Date:  2014-07-01       Impact factor: 3.902

3.  Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.

Authors:  Stephen J Nicholls; W H Wilson Tang; Danielle Brennan; Marie-Luise Brennan; Shirley Mann; Steven E Nissen; Stanley L Hazen
Journal:  Clin Chem       Date:  2011-09-22       Impact factor: 8.327

4.  Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach.

Authors:  Paul Welsh; Eliana Polisecki; Michele Robertson; Sabine Jahn; Brendan M Buckley; Anton J M de Craen; Ian Ford; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; James Shepherd; Aroon D Hingorani; George Davey Smith; Ernst Schaefer; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

Review 5.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

6.  C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta.

Authors:  Karen J Ho; Christopher D Owens; Thomas Longo; Xin X Sui; Cristos Ifantides; Michael S Conte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-11       Impact factor: 4.733

7.  C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells.

Authors:  Xinwen Wang; Dan Liao; Uddalak Bharadwaj; Min Li; Qizhi Yao; Changyi Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12-20       Impact factor: 8.311

8.  Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation.

Authors: 
Journal:  Eur J Epidemiol       Date:  2008-04-19       Impact factor: 8.082

9.  C-reactive protein, inflammatory conditions, and cardiovascular disease risk.

Authors:  Ravi Dhingra; Philimon Gona; Byung-Ho Nam; Ralph B D'Agostino; Peter W F Wilson; Emelia J Benjamin; Christopher J O'Donnell
Journal:  Am J Med       Date:  2007-12       Impact factor: 4.965

10.  Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?

Authors:  Virginia B Kraus; Joanne M Jordan
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.